Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. has successfully passed the review for listing on the Sci-Tech Innovation Board, moving closer to its IPO after overcoming various challenges, including the expiration of financial documents [1] Fundraising and Financials - The company plans to raise approximately 2.4 billion yuan through the issuance of nearly 90 million shares, significantly lower than the previously planned 3.5 billion yuan [2][4] - The funds will be allocated to three main projects: 1.655 billion yuan for the construction of a recombinant human albumin industrialization base, over 600 million yuan for new drug research and development, and 100 million yuan for working capital [2][3] - The total investment for the recombinant human albumin industrialization base project is 1.909 billion yuan, with an expected annual production capacity of 120 tons of OsrHSA raw liquid [3] Revenue and Business Performance - The company has reported continuous losses over the past three years, with revenues of 13.4 million yuan in 2022, 24.3 million yuan in 2023, and an estimated 25.2 million yuan in 2024, while net profits were -122 million yuan, -187 million yuan, and -151 million yuan respectively [8][10] - The main source of revenue comes from pharmaceutical excipients and research reagents, with a small portion from beauty products, which accounted for less than 5% of total revenue [5][10] Legal Issues - The company is involved in a patent infringement lawsuit initiated by Ventria Bioscience, which claims that Heyuan's products infringe on its patents. The case has been ongoing since 2020, with a recent counter-suit filed by Heyuan against Ventria [12][13]

Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. is set to be the first company reviewed by the Sci-Tech Innovation Board under the new listing standards, focusing on innovative technology in biopharmaceuticals, specifically using rice to produce recombinant human albumin, addressing supply bottlenecks in critical bioproducts [1][2]. Group 1: Market Opportunity - The market for human serum albumin in China reached 36.1 billion yuan in 2023, with projections to grow to 57 billion yuan by 2030, yet over 60% of the supply is reliant on imports [2]. - The company targets this market gap by utilizing rice as a "bioreactor" to produce high-purity recombinant human albumin, significantly enhancing domestic production capabilities [2][3]. Group 2: Technological Innovation - Heyuan Biotechnology has developed two key technology platforms: Oryz HiExp for high expression of OsrHSA and Oryz Pur for efficient purification, achieving a purity level of over 99.9999% [3]. - The innovative "rice blood-making" technology has gained recognition, with the founder's story highlighted as a model of innovation in the biopharmaceutical field [3]. Group 3: Product Pipeline and Clinical Trials - The core product, HY1001, is expected to complete its Phase III clinical trial for treating liver cirrhosis-related hypoalbuminemia by May 2024, showing efficacy comparable to plasma-derived albumin [4]. - If approved, HY1001 will be the world's first recombinant protein drug produced using rice cell expression systems, providing a sustainable solution to the reliance on imported human albumin [5]. Group 4: Future Prospects and Funding - The company plans to raise 240 million yuan to expand its production capacity from 10 tons to 130 tons annually and to support new drug development projects [8]. - Upon full implementation, Heyuan Biotechnology aims to establish a complete industrial chain from "medicinal rice cultivation to albumin extraction and drug manufacturing" [9].